Ledger.Open graph →
SEC Form D · filed April 1, 2025

Imbria Pharmaceuticals, Inc

Offering
$124.2M
Sold
$59.2M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
BOSTON, MA
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (16)

Andrew Levin · Boston, MADirectorAlvin Shih · Boston, MADirectorKomal Joshi · Boston, MAExecCharles Dunn · Boston, MADirectorRebecca Luse · Greenwich, CTDirectorAlvin Shih · Boston, MADirectorKomal Joshi · Boston, MAExecCharles Dunn · Boston, MADirectorAndrew Levin · Boston, MADirectorJames Januzzi · Boston, MADirectorKeith Grimes · Houston, TXExecEdward Gillespie · Houston, TXDirectorPeter Longo · Houston, TXDirectorLucie Harwood · Houston, TXDirectorRebecca Luse · Greenwich, CTDirectorJames Januzzi · Boston, MADirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗